- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05528354
Venetoclax and Decitabin Based Conditioning Regimen Followed With Post-HSCT Decitabin Maintenance Therapy in TP53 Mutant AML/MDS Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Yanmin Zhao, PhD
- Phone Number: +8615858199217
- Email: yanminzhao@zju.edu.cn
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310006
- Recruiting
- The First Hospital of Zhejiang Medical Colleage Zhejiang University
-
Contact:
- Yanmin Zhao, PhD
- Phone Number: +8615858199217
- Email: yanminzhao@zju.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- AML or MDS diagnosed according to 2016 WHO criteria with TP53 mutation before enrollment;
- Aged from 12 to 70 years;
- The Eastern Cooperative Oncology Group (ECOG) performance score of 0-2;
- Creatinine clearance rate ≥ 60 mL/min (according to Cockcroft-Gault formula);
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≥ 3× upper limit of normal range (ULN), total bilirubin ≤ 2×ULN;
- Left ventricular ejection fraction (LVEF) assessed by echocardiography (ECHO) ≥ 45%;
- Life expectancy > 8 weeks;
- Sign the informed consent voluntarily, understand and comply with all trial requirements.
Exclusion Criteria:
- Active autoimmune diseases, such as SLE, rheumatoid arthritis, etc.
- Current active cardiovascular disease with clinically significance, such as uncontrolled arrhythmias, uncontrolled hypertension, congestive heart failure, any grade 3 or 4 heart disease determined by the New York Heart Association (NYHA) functional classification, or a history of myocardial infarction within the 6 months prior to screening;
- Other serious medical conditions (e.g., advanced infection) that may limit the patient's participation in the trial;
- Known human immunodeficiency virus (HIV) infection, or drug-uncontrolled chronic infection of hepatitis B virus (HBV-DNA > 1000IU/ml) or hepatitis C virus (anti-HCV positive);
- Pregnant or lactating women;
- Fail to understand, comply with the study protocol or sign the informed consent form.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: VEN and DEC based conditioning regimen followed with post-HSCT DEC maintenance therapy
|
Patients with age<50 years and HCT-CI<3: Haploidentical transplantation: AraC 2g/m2 d-10~d-9, BU 0.8mg/kg q6h d-8~-6, CTX 1.8g/m2 d-5~d-4, Meccnu 250mg/m2 d-3, ATG 1.5mg/kg/d d-5~-2, VEN 400mg/d d-15~-9, DEC 20mg/m2 d-15~-11; HLA-matched transplantation: BU 0.8mg/kg q6h d-7~-4, CTX 60mg/kg d-3~d-2, Meccnu 250mg/m2 d-1, VEN d-12~-8, DEC 20mg/m2 d-12~-6, and ATG for the unrelated donor type. Patients with age>50 years or HCT-CI≥3: Flu 30mg/m2 d-10~-5, BU 0.8mg/kg q6h d-7~-5, Meccnu 250mg/m2 d-4, ATG 7.5mg/kg divided into d-4~-1, VEN d-15~-9, DEC 20mg/m2 d-15~-11. Note: if Voriconazole or Posaconazole is used to prevent or treat fungal infections, VEN should be 200mg/d for 7 consecutive days. In the time window of 60-120 days after transplantation: DEC 5mg/m2/d for 5 consecutive days every 6 to 8 weeks with a total of 4 to 6 courses if there is no severe aGVHD (grade 3 or higher) and the donor chimerism rate of bone marrow blood (STR)>95%. If the MRD turns positive, DLI can be performed. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: At Year 1
|
The time from transplantation to the occurrence of any of the following:
Leukemia blasts reappeared in peripheral blood, or blasts ≥ 5%, naive monocytes ≥ 5% in bone marrow, or extramedullary lesions. |
At Year 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS)
Time Frame: At Year 1
|
Assessment of OS at Year 1
|
At Year 1
|
Cumulative relapse rate
Time Frame: At Year 1
|
Assessment of cumulative relapse rate at Year 1
|
At Year 1
|
Non-relapse mortality (NRM)
Time Frame: At Year 1
|
Assessment of NRM at Year 1
|
At Year 1
|
Acute graft-versus-host disease (GVHD)
Time Frame: At Day 100
|
Acute GVHD incidence
|
At Day 100
|
Chronic graft-versus-host disease (GVHD)
Time Frame: through study completion, an average of 1 year
|
Chronic GVHD incidence
|
through study completion, an average of 1 year
|
Adverse effects
Time Frame: through study completion, an average of 1 year
|
Drug related adverse effects
|
through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- IIT20220036C-R1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematopoietic Stem Cell Transplantation
-
Washington University School of MedicineNational Marrow Donor Program; Predictive BioDiagnostics, LLCCompletedHematopoietic Stem Cell Transplantation | Stem Cell Transplantation, Hematopoietic | Transplantation, Hematopoietic Stem CellUnited States
-
University Hospital, GenevaRecruitingAllogeneic Hematopoietic Stem Cell Transplantation | Hematopoietic Stem Cell Transplantation | Autologous Hematopoietic Stem Cell TransplantationSwitzerland
-
Universitaire Ziekenhuizen KU LeuvenUnknownHematopoietic Stem Cell Transplantation | Hematopoietic Stem Cell Transplantation, Allogeneic
-
Hongnan MoUnknownHematopoietic Stem Cell Transplantation | Thrombocytopoietin | Hematopoietic Stem Cell MobilizationChina
-
University of OsloRecruitingHematopoietic Stem Cell TransplantationNorway
-
Seoul National University HospitalNational Institute of Food and Drug Safety Evaluation (Republic of Korea)Not yet recruitingHematopoietic Stem Cell Transplantation
-
Seoul National University HospitalNational Institute of Food and Drug Safety Evaluation (Republic of Korea)RecruitingHematopoietic Stem Cell TransplantationKorea, Republic of
-
The First Affiliated Hospital of Soochow UniversityThe First Affiliated Hospital of Zhengzhou University; Children's Hospital... and other collaboratorsRecruitingHematopoietic Stem Cell TransplantationChina
-
University of Alabama at BirminghamMiltenyi Biotec, Inc.Active, not recruitingHematopoietic Stem Cell TransplantationUnited States
-
Nantes University HospitalCompletedHematopoietic Stem Cell TransplantationFrance
Clinical Trials on VEN and DEC based conditioning regimen
-
Nanfang Hospital of Southern Medical UniversitySun Yat-Sen Memorial Hospital of Sun Yat-Sen University; First People's Hospital... and other collaboratorsCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid Leukemia | Gene Abnormality | Cytogenetic AbnormalityChina
-
Shanghai Jiao Tong University School of MedicineRecruiting
-
First Affiliated Hospital Xi'an Jiaotong UniversityNot yet recruitingAllogeneic Hematopoietic Stem Cell Transplantation | Central Nervous System LeukemiaChina
-
Peking University People's HospitalRecruitingAcute Myeloid LeukemiaChina
-
Assiut UniversityUnknown
-
Kiadis PharmaNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsWithdrawnMyelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML)United States
-
Washington University School of MedicineRecruitingHemoglobinopathies | Bone Marrow Failure Syndromes | Metabolic Disorders | Non-malignant Disorders | Severe Sickle Cell Disease | Immunologic DisordersUnited States
-
Sun Yat-sen UniversityRecruitingGlucose Metabolism Disorders | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | Metabolic DiseaseChina
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedKidney Transplantation | End-stage Renal Disease | Renal TransplantationUnited States
-
Kaiser PermanentePatient-Centered Outcomes Research Institute; OneFlorida Clinical Research...Completed